losartan has been researched along with Anasarca in 12 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm." | 2.90 | Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. ( Carpentier, AF; Charissoux, M; Chinot, O; Cuzzubbo, S; Ducray, F; Hoang-Xuan, K; Le Rhun, E; Levy-Piedbois, C; Mandonnet, E; Portal, JJ; Psimaras, D; Quillien, V; Ricard, D; Sejalon, F; Thomas, L; Tibi, A; Ursu, R; Vicaut, E, 2019) |
| "Losartan has an antimigratory effect, reducing leukocyte migration by reducing ICAM-1 and P-selectin expression." | 1.33 | Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. ( Carvalho, MH; Cruz, JW; Fortes, ZB; Martinez, LL; Miguel, AS; Nigro, D; Oliveira, MA; Rastelli, VM; Tostes, RC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Datta, M | 1 |
| Chatterjee, S | 1 |
| Perez, EM | 1 |
| Gritsch, S | 1 |
| Roberge, S | 1 |
| Duquette, M | 1 |
| Chen, IX | 1 |
| Naxerova, K | 1 |
| Kumar, AS | 1 |
| Ghosh, M | 1 |
| Emblem, KE | 1 |
| Ng, MR | 1 |
| Ho, WW | 1 |
| Kumar, P | 1 |
| Krishnan, S | 1 |
| Dong, X | 1 |
| Speranza, MC | 1 |
| Neagu, MR | 1 |
| Iorgulescu, JB | 1 |
| Huang, RY | 1 |
| Youssef, G | 1 |
| Reardon, DA | 1 |
| Sharpe, AH | 1 |
| Freeman, GJ | 1 |
| Suvà, ML | 1 |
| Xu, L | 1 |
| Jain, RK | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Diaz, JH | 1 |
| Ursu, R | 1 |
| Thomas, L | 1 |
| Psimaras, D | 1 |
| Chinot, O | 1 |
| Le Rhun, E | 1 |
| Ricard, D | 1 |
| Charissoux, M | 1 |
| Cuzzubbo, S | 1 |
| Sejalon, F | 1 |
| Quillien, V | 1 |
| Hoang-Xuan, K | 1 |
| Ducray, F | 1 |
| Portal, JJ | 1 |
| Tibi, A | 1 |
| Mandonnet, E | 1 |
| Levy-Piedbois, C | 1 |
| Vicaut, E | 1 |
| Carpentier, AF | 1 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Mohapatra, A | 1 |
| Matthai, SM | 1 |
| Vijayakumar, K | 1 |
| Basu, G | 1 |
| Handler, J | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Martinez, LL | 1 |
| Oliveira, MA | 1 |
| Miguel, AS | 1 |
| Rastelli, VM | 1 |
| Cruz, JW | 1 |
| Tostes, RC | 1 |
| Carvalho, MH | 1 |
| Nigro, D | 1 |
| Fortes, ZB | 1 |
| Laudanno, OM | 1 |
| Cesolari, JA | 1 |
| Blais, C | 1 |
| Leclair, P | 1 |
| Molinaro, G | 1 |
| Adam, A | 1 |
| Raghavendra, V | 1 |
| Kulkarni, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial[NCT01805453] | Phase 3 | 80 participants (Actual) | Interventional | 2013-03-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for losartan and Anasarca
| Article | Year |
|---|---|
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Brain Neoplasms; Chemoradio | 2019 |
11 other studies available for losartan and Anasarca
| Article | Year |
|---|---|
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Topics: Animals; CD8-Positive T-Lymphocytes; Edema; Glioblastoma; Immune Checkpoint Inhibitors; Losartan; Mi | 2023 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Hypersensitivity Reaction to Yellow Jacket Sting in a Previously Nonallergic Patient Taking an Angiotensin Receptor Blocker.
Topics: Aged; Angiotensin Receptor Antagonists; Animals; Anti-Allergic Agents; Diphenhydramine; Edema; Human | 2017 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
Quiz page: an unusual cause of nephrotic syndrome.
Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension | 2015 |
Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Blood Pressure; Calcium Channel Blockers; Drug Therapy | 2010 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Cell Adhe | 2005 |
[Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl | 2006 |
Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations-induced paw edema model in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Carrageenan; Dos | 1999 |
AT1 receptor antagonism enhances angiotensin-II-facilitated carrageenan-induced paw edema.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |